Johnson & Johnson diskutieren
Johnson & Johnson
WKN: 853260 / Symbol: JNJ / Name: Johnson & Johnson / Aktie / Pharmazeutika / Large Cap /
151,98 €
1,40 %
Johnson & Johnson (NYSE: JNJ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $215.00 price target on the stock.
Ratings data for JNJ provided by MarketBeat
Johnson & Johnson (NYSE: JNJ) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating. They now have a $180.00 price target on the stock, up previously from $167.00.
Ratings data for JNJ provided by MarketBeat
Johnson & Johnson (NYSE: JNJ) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $178.00 price target on the stock.
Ratings data for JNJ provided by MarketBeat
Johnson & Johnson (NYSE: JNJ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for JNJ provided by MarketBeat
Johnson & Johnson (NYSE: JNJ) had its price target raised by analysts at Raymond James from $172.00 to $175.00. They now have an "outperform" rating on the stock.
Ratings data for JNJ provided by MarketBeat
Johnson & Johnson (NYSE: JNJ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $215.00 price target on the stock.
Ratings data for JNJ provided by MarketBeat
Johnson & Johnson (NYSE: JNJ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $215.00 price target on the stock.
Ratings data for JNJ provided by MarketBeat
Johnson & Johnson (NYSE: JNJ) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $181.00 price target on the stock.
Ratings data for JNJ provided by MarketBeat
Johnson & Johnson (NYSE: JNJ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $215.00 price target on the stock.
Ratings data for JNJ provided by MarketBeat
Johnson & Johnson (NYSE: JNJ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $215.00 price target on the stock.
Ratings data for JNJ provided by MarketBeat
Johnson & Johnson (NYSE: JNJ) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $181.00 price target on the stock.
Ratings data for JNJ provided by MarketBeat
Johnson & Johnson (NYSE: JNJ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $215.00 price target on the stock.
Ratings data for JNJ provided by MarketBeat
Johnson & Johnson (NYSE: JNJ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $215.00 price target on the stock.
Ratings data for JNJ provided by MarketBeat
Johnson & Johnson (NYSE: JNJ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $215.00 price target on the stock.
Ratings data for JNJ provided by MarketBeat
Johnson & Johnson (NYSE: JNJ) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $175.00 price target on the stock.
Ratings data for JNJ provided by MarketBeat
Johnson & Johnson (NYSE: JNJ) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $175.00 price target on the stock.
Ratings data for JNJ provided by MarketBeat
Johnson & Johnson (NYSE: JNJ) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $175.00 price target on the stock.
Ratings data for JNJ provided by MarketBeat
Johnson & Johnson (NYSE: JNJ) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $175.00 price target on the stock.
Ratings data for JNJ provided by MarketBeat
Johnson & Johnson (NYSE: JNJ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $215.00 price target on the stock.
Ratings data for JNJ provided by MarketBeat
Johnson & Johnson (NYSE: JNJ) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for JNJ provided by MarketBeat
Neueste Beiträge
HC_Wainwright in Arrowhead Pharmaceuticals Inc. diskutieren